DrugPatentWatch Database Preview

TYGACIL Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Tygacil patents expire, and what generic alternatives are available?

Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-eight countries.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tigecycline profile page.

Summary for TYGACIL

International Patents:	59
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	76
Clinical Trials:	5
Patent Applications:	1,357
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYGACIL
DailyMed Link:	TYGACIL at DailyMed

Pharmacology for TYGACIL

Ingredient-type	Tetracyclines
Drug Class	Tetracycline-class Antibacterial

Synonyms for TYGACIL

(4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide

(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

(4S,4aS,5aR,12aS)-9-(2-(tert-Butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1

(4S,4AS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxa

(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

(4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

(4S,4aS,5aR,12aS)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide

(4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

121GE002

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-[[[(1,1-DIMETHYLETHYL)AMINO]ACETYL]AMINO]-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

220620-09-7

220620-09-7 (anhy.)

620T097

70JE2N95KR

9-t-Butylglycylamido minocycline

9-t-Butylglycylamido-minocycline hydrate

9-tert-Butylglycylamidominocycline

A5226

AB0011463

AB01566818_01

AB2000089

AC-1798

AC1NQZEU

AC1O714W

ACT08710

AK-73038

AKOS015895663

AKOS025401452

AM20090708

AN-6306

BC677670

BCPP000045

BR-73038

C12012

C29H39N5O8

CAS-220620-09-7

CHEBI:149836

CHEMBL376140

CS-1876

CT0198

D01079

D0G4OD

DB00560

DSSTox_CID_28507

DSSTox_GSID_48581

DSSTox_RID_82779

DTXSID2048581

FPZLLRFZJZRHSY-HJYUBDRYSA-N

FT-0657279

GAR 936

GAR-936

GAR-936,Tigecycline

Glycylcycline

HY-B0117

I06-1089

LS-186580

LS-187002

LS-187782

MFCD00935753

MLS006010079

MolPort-009-199-379

MolPort-028-751-260

N-((5aR,6aS,7S,10aS,Z)-9-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl)-2-(tert-butylamino)acetamide

N-[(5aR,6aS,7S,9E,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide

N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide

N-[(5AR,6AS,7S,9Z,10AS)-9-[AMINO(HYDROXY)METHYLIDENE]-4,7-BIS(DIMETHYLAMINO)-1,10A,12-TRIHYDROXY-8,10,11-TRIOXO-5,5A,6,6A,7,8,9,10,10A,11-DECAHYDROTETRACEN-2-YL]-2-(TERT-BUTYLAMINO)ACETAMIDE

N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide

NCGC00183095-01

PL010867

PL050681

PubChem21336

Q-101396

RL02680

S-5066

s1403

SC-20200

SCHEMBL101795

SCHEMBL105082

SCHEMBL237962

SMR002530064

SOVUOXKZCCAWOJ-HJYUBDRYSA-N

ST2413997

SYN3024

TBG-MINO

Tigeciclina

Tigecyclin

Tigecycline

Tigecycline (JAN/USAN)

Tigecycline [USAN:INN:BAN]

Tigecycline [USAN]

Tigecycline hydrate

Tigecycline, Antibiotic for Culture Media Use Only

Tigecyclinum

Tigilcycline

Tox21_112910

Tygacil (TN)

Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline

Tygacil;GAR-936;WAY-GAR-936;TBG-MINO

Tygacil(TM)

UNII-70JE2N95KR

WAY-GAR-936

ZINC100022633

ZINC102200515

ZINC14879972

US Patents and Regulatory Information for TYGACIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005	AP	RX	Yes	Yes			Y
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005	AP	RX	Yes	Yes			Y
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005	AP	RX	Yes	Yes			Y
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005	AP	RX	Yes	Yes			Y

  Purchase this report

see a sample report or, see our see our flat-rate plans

Expired US Patents for TYGACIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005
Pf Prism Cv	TYGACIL	tigecycline	POWDER;IV (INFUSION)	021821-001	Jun 15, 2005

Paragraph IV (Patent) Challenges for TYGACIL

Drugname	Dosage	Strength	RLD	Submissiondate
	For Injection	50 mg per vial		2009-06-15

  Purchase this report

see a sample report or, see our see our flat-rate plans

International Patents for TYGACIL

Country	Document Number	Estimated Expiration
South Korea	20080002828
Cyprus	1114504
Honduras	2006011218
Canada	2609875

Supplementary Protection Certificates for TYGACIL

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB06/033	United Kingdom		PRODUCT NAME: TIGECYCLINE
0244	Netherlands		PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
06/030	Ireland		PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
00244	Netherlands		PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424